• Shantanu B Kuchekar Research Scholar,Rajarambapu College of Pharmacy, Kasegaon
  • Shrinivas K Mohite


Objective: The short biological half-life of Ranolazine (RAN) and consequently the difficulties in maintaining the desired concentrations in the
blood, determined the need for the development of an extended release formulation which can achieved by developing a matrix tablet using Eudragit
L100-55. Furthermore, including some materials like polyvinylpyrrolidone to liquid medication (microsystems), it would be possible to produce dry
powder formulations containing liquid with high concentration of the drug. The aim of the present study was to develop RAN liquisolid tablets using
Plackett–Burman (PB) design to screen the effect of five formulation and process factors on the formulation.
Methods: RAN liquisolid tablets were prepared by liquisolid technique using PB design to screen the effect of five formulation and process factors. The
RAN liquisolid formulations were characterized by pre and post compression parameters, differential scanning calorimetry, powder X-ray diffraction,
scanning electron microscopy, and in-vitro drug release.
Results: Parameters such as Neusilin US2, Aerosil 200, polyethylene glycol grades (PEG) 400, polyvinyl pyrrolidone (PVP) K30, and Eudragit L100-
55 showed an influential effect on the selected responses angle of repose, thickness, and hardness as observed in Pareto charts of PB design. Hence,
liquisolid technique was selected to develop the extended release liquisolid tablets of RAN.
Conclusion: PB design was proved to be appropriate tool to study effect of Neusilin US2, Aerosil 200, PEG 400, PVP K30, and Eudragit L100-55 on the
response variables and to recognize the most influencing factor by using liquisolid technique.

Keywords: Ranolazine, Liquisolid technique, Eudragit L100 55, Plackett–Burman.


Author Biography

Shantanu B Kuchekar, Research Scholar,Rajarambapu College of Pharmacy, Kasegaon



Perrie Y, Rades T. Fasttrack-Pharmaceutics: Drug Delivery and Targeting. United Kingdom: Pharmaceutical Press; 2012.

Pranav S, Bhargavi N, Chandarana Z. Optimization of formulation variables of ranolazine extended-release tablets by 32 full factorial design. Pharmagene 2013;1(2):1-9.

Anderson JR, Nawarskas JJ. Ranolazine. A metabolic modulator for the treatment of chronic stable angina. Cardiol Rev 2005;13(4):202-10.

Bidada J, Gonjari I, Bhusari A, Raut C, Dhule A. Development of extended release matrix tablets of Ranolazine containing polyacrylic and ethylcellulose polymers. Der Pharm Lett 2011;3(4):215-26.

United States Pharmacopeia Pending Monograph Draft 1 - For Public Comment, 2013.

Available from:

Available from:

WC500045937, Summary of Product characterization, Date of first authorization: [09 July 2008], Date of last renewal. [06 March 2013]. p30-4.

European Medicines agency Evaluation of medicines for Human use (EMEA), CHMP Assessment Report for Latixa for Ranolazine, Doc. Ref: EMEA/CHMP/30876/2008.

Singh DH, Vaidya IS. Optimization and evaluation of ranolazine extended release matrix tablets. J Pharm Res 2014;3(3):26-31.

Priya MR, Natarajan R, Rajendran NN. Design and in vitro evaluation of sustained release tablets of ranolazine. Int J Pharm Sci Res 2011;2(3):922-8.

Javadzadeh Y, Jafari-Navimipour B, Nokhodchi A. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine). Int J Pharm 2007;341(1-2):26-34.

Nagar SK, Patel VH, Patel VA, Siju VV. Design, development and optimization of olmesartan medoxomil liquisolid tablets using central composite design. Pharma Tutor 2013.

Fahmy RH, Kassem MA. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: In vitro and in vivo evaluation. Eur J Pharm Biopharm 2008;69(3):993-1003.

Kaur M, Bala R, Arora S. Formulation and evaluation of liquisolid compacts of amlodipine besylate. Int Res J Pharm 2013;4(1):156-60.

Tiong N, Elkordy AA. Effects of liquisolid formulations on dissolution of naproxen. Eur J Pharm Biopharm 2009;73(3):373-84.17. Ashwin B. Kuchekar, Atmaram B. Pawar. Screening of factors using plackett burman design in the preparation of capecitabine-loaded nano-polymeric micelles. Int J Pharm Pharm Sci 2014;6(5):489-96.

Shah SR, Parikh RH, Chavda JR, and Sheth NR. Application of plackett–burman screening design for preparing glibenclamide nanoparticles for dissolution enhancement. Powder Technol 2013;235:405-11.

El-Malah Y, Nazzal S. Hydrophilic matrices: Application of Placket-Burman screening design to model the effect of POLYOX-carbopol blends on drug release. Int J Pharm 2006;309(1-2):163-70.

Moscoso-Pérez C, Moreda-Piñeiro J, López-Mahía P, Muniategui-Lorenzo S, Fernández-Fernández E, Prada-Rodríguez D. Direct determination of Ge in hot spring waters and coal fly ash samples by hydride generation-ETAAS. Talanta 2004;64(2):302-7.

Statgraphics Plus, 5.1 for Windows, Statistical Graphic Crop. Online Manuals; 2001.

Lachmman L, Liberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. 3rd ed. Bombay: Vargheese Publishing House; 1991. p. 430.

Gudikandula R, Madhavi K, Thakkalapally SR, Veeramalla A, Prasad IR. Enhancement of solubility and dissolution rate of ezetimibe through liquisolid technique. Int J Pharma Sci Res 2013;4(8):3229-38.

Mahajan HS, Dhamne MR, Gattani SG, Rasal AD, Shaikh HT. Enhanced dissolution rate of glipizide by a liquisolid technique. Int J Pharm Sci Nanotechnol 2011;3(4):1205-13.

Prajapati ST, Joshi HA, Patel CN. preparation and characterization of self-microemulsifying drug delivery system of olmesartan medoxomil for bioavailability improvement. J Pharm 2013;Article ID 728425, 1-9.



How to Cite

Kuchekar, S. B., and S. K. Mohite. “DESIGN AND EVALUATION OF EXTENDED RELEASE RANOLAZINE LIQUISOLOID TABLETS USING PLACKETT BURMAN SCREENING DESIGN”. Asian Journal of Pharmaceutical and Clinical Research, vol. 8, no. 3, May 2015, pp. 292-00,



Original Article(s)